1. Takara Bio Inc.
  2. Investor Relations
  3. IR News
IR News
サブ-ナビゲーション
  • information
  • News
  • Corporate Guide
  • Business
  • Investor Relations
    • Management Policy
    • Financial Data
    • IR Library
    • Stock Information
    • IR Calendar
    • 現在位置:IR News
    • FAQ
    • Contact IR
    • Disclosure Policy
    • User Guide
  • Sustainability
  • Contact Us

IR News

  • 2025/05/13 Notice of Changes in Representative Directors pdf (140KB)
  • 2025/05/13 Notice Concerning Dividend from Surplus pdf (137KB)
  • 2025/05/13 Consolidated Financial Results for the FY Ended March 31 2025 pdf (478KB)
  • 2025/05/01 (Progress of Matters Previously Disclosed) Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary pdf (233KB)
  • 2025/03/28 [Delayed] Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary pdf (267KB)
  • 2025/02/13 Notice Concerning Revisions to the Financial Results Forecasts pdf (182KB)
  • 2025/02/13 Consolidated Financial Results for the Nine Months Ended December 31, 2024 (Under Japanese GAAP) pdf (431KB)
  • 2025/01/27 Notice Concerning Acquisition of Shares of ViSpot, Inc. (to Make It a Subsidiary) pdf (220KB)
  • 2025/01/15 Notice Concerning Acquisition of Shares of Curio Bioscience, Inc. (to Make It a Subsidiary) pdf (245KB)
  • 2024/11/08 Notice Concerning Differences between the Financial Forecast and the Actual Results pdf (209KB)
  • 2024/11/08 Consolidated Financial Results for the Six Months Ended September 30, 2024 (Under Japanese GAAP) pdf (443KB)
  • 2024/08/08 Consolidated Financial Results for the Three Months Ended June 30, 2024 (Under Japanese GAAP) pdf (233KB)
  • 2024/07/31 [Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2024 pdf (1,059KB)
  • 2024/06/27 Matters Concerning Controlling Shareholders pdf (184KB)
  • 2024/05/28 Notice of the 22nd Annual General Meeting of Shareholders pdf (201KB)
  • 2024/05/10 Notice Concerning Dividends from Surplus pdf (139KB)
  • 2024/05/10 Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (Under Japanese GAAP) pdf (445KB)
  • 2024/02/14 Consolidated finacial results for the nine months ended Dec 31(Under Japanese GAAP) pdf (368KB)
  • 2023/11/09 Notice Concerning Differences between the Financial Results Forecasts and the Actual Results pdf (163KB)
  • 2023/11/09 Notice Concerning Revisions to the Financial Results Forecasts pdf (177KB)
  • 2023/11/09 Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP) pdf (427KB)
  • 2023/08/30 {Delayed] Corporate Governance Report pdf (1,523KB)
  • 2023/08/08 Consolidated Financial Results for the Three Months Ended June 30, 2023 (Under Japanese GAAP) pdf (424KB)
  • 2023/08/08 Notice Concerning Revisions to the First Half Financial Results Forecasts pdf (179KB)
  • 2023/07/31 [Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2023 pdf (1,551KB)
  • 2023/06/29 Matters Concerning Controlling Shareholders pdf (241KB)
  • 2023/05/11 Notice Concerning Dividends from Surplus pdf (232KB)
  • 2023/05/11 Takara Bio Group Formulated “Medium-Term Management Plan 2026” pdf (350KB)
  • 2023/05/11 Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (Under Japanese GAAP) pdf (610KB)
  • 2023/03/02 ARTICLES OF INCORPORATION pdf (111KB)
  • 2023/02/09 Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend Increase) pdf (252KB)
  • 2023/02/09 Consolidated Financial Results for the Nine Months Ended December 31, 2022(Under Japanese GAA) pdf (456KB)
  • 2023/01/25 [Delayed]Takara Bio Announces Transfer of SAKIGAKE and Orphan Designations for NY-ESO-1/siTCR Gene Therapy Product pdf (229KB)
  • 2022/11/10 Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend Increase) pdf (186KB)
  • 2022/11/10 Consolidated Financial Results for the Six Months Ended September 30, 2022 (Under Japanese GAAP) pdf (404KB)
  • 2022/10/25 Notice Concerning Revisions to the First Half Financial Results Forecasts pdf (244KB)
  • 2022/09/16 [Correction] Annual Securities Report for the Fiscal Year Ended March 31, 2022 pdf (212KB)
  • 2022/09/06 Annual Report 2022 pdf (8,041KB)
  • 2022/08/29 [Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2022 pdf (1,191KB)
  • 2022/08/04 Consolidated Financial Results for the Three Months Ended June 30, 2022 (Under Japanese GAAP) pdf (394KB)
  • 2022/07/06 [Delayed] Corporate Governance Report pdf (770KB)
  • 2022/06/13 Notice of the 20th Annual General Meeting of Shareholders pdf (208KB)
  • 2022/05/12 Notice of Dividends of Surplus pdf (135KB)
  • 2022/05/12 Consolidated Financial Statements for the Year Ended March 31, 2022 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED] pdf (350KB)
  • 2022/02/10 Notice Concerning Forecast Revisions of Financial Results and Dividend (Dividend Increase) pdf (250KB)
  • 2022/02/10 Consolidated Financial Statements for the Third Quarter Ended December 31, 2021 FY2022 (April 1, 2021-March 31, 2022) [UNAUDITED] pdf (771KB)
  • 2022/01/24 Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization pdf (248KB)
  • 2022/01/20 [Delayed] Corporate Governance Report pdf (768KB)
  • 2021/11/09 Notice of Revisions of Financial Forecast and Dividend Forecast (Dividend Increase) pdf (138KB)
  • 2021/11/09 Consolidated Financial Statements for the Second Quarter Ended September 30, 2021 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED] pdf (339KB)
  • 2021/10/21 Notice of Revision of Financial Forecast pdf (241KB)
  • 2021/09/21 Notice of Resolution of the Board of Directors on Selection of “Prime Market” Listing on the Tokyo Stock Exchange under the New Market Segments pdf (224KB)
  • 2021/08/06 [Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED] pdf (596KB)
  • 2021/08/06 [Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED] pdf (154KB)
  • 2021/08/03 Notice of Revision of Financial Forecast and Dividend Forecast (Dividend Increase) pdf (139KB)
  • 2021/08/03 Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) 〔UNAUDITED〕 pdf (596KB)
  • 2021/05/13 Consolidated Financial Statements for the Year Ended March 31, 2021 FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED] pdf (695KB)
  • 2021/02/10 Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase) pdf (287KB)
  • 2021/02/10 Consolidated Financial Statements for the Third Quarter Ended December 31, 2020 FY2021 (April 1, 2020 - March 31, 2021)[UNAUDITED] pdf (915KB)
  • 2021/01/05 Corporate Governance Report pdf (681KB)
  • 2020/11/25 We have posted "Financial Results Presentation". pdf (1,020KB)
  • 2020/11/10 Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase) pdf (217KB)
  • 2020/11/10 Consolidated Financial Statements for the Second Quarter Ended September 30, 2020 FY2021 (April 1, 2020 - September 30, 2020) [UNAUDITED] pdf (681KB)
  • 2020/11/06 We have issued "Annual Report 2020". pdf (1,023KB)
  • 2020/10/21 【Delayed】Announcement on Revision of Financial Forecast pdf (225KB)
  • 2020/08/05 【Delayed】Announcement on revision of financial forecast pdf (369KB)
  • 2020/08/05 【Delayed】Consolidated Financial Statements for the First Quarter Ended June 30, 2020 FY2021 (April 1, 2020 - June 30, 2020) pdf (780KB)
  • 2020/08/04 Summary of Financial Results for the first quarter 2021 pdf (366KB)
  • 2020/08/04 Takara Bio terminates the license agreement relating to Oncolytic Virus C-REV with Tasly Biopharmaceuticals, China pdf (285KB)
  • 2020/06/26 We have posted "Financial Results Presentation". pdf (670KB)
  • 2020/06/08 Takara Bio Group’s Formulation of Long-Term Management Plan FY2026 and Medium-Term Management Plan FY2023 pdf (994KB)
  • 2020/05/28 Notice of the 18th Annual General Meeting of Shareholders pdf (163KB)
  • 2020/05/19 【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2020 FY2020 (April 1, 2019 -March 31, 2020)[UNAUDITED] pdf (710KB)
  • 2020/05/14 Summary of Financial Results 2020 pdf (430KB)
  • 2020/05/13 【Delayed】Takara Bio has entered into a license agreement relating to C-REV with Tasly Biopharmaceuticals, China pdf (227KB)
  • 2020/02/13 Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED] pdf (625KB)
  • 2019/11/21 We have posted "financial results presentation". pdf (551KB)
  • 2019/11/12 Consolidated Financial Statements for the Second Quarter Ended September 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED] pdf (626KB)
  • 2019/09/27 Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV pdf (247KB)
  • 2019/09/27 We have issued "Annual Report 2019". pdf (1,044KB)
  • 2019/08/14 Corporate Governance Report pdf (514KB)
  • 2019/08/06 Consolidated Financial Statements for the First Quarter Ended June 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED] pdf (583KB)
  • 2019/05/30 Notice of the 17th Annual General Meeting of Shareholders pdf (148KB)
  • 2019/05/22 We have posted "Financial Results Presentation". pdf (820KB)
  • 2019/05/14 Consolidated Financial Statements for the Year Ended March 31, 2019 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED] pdf (795KB)
  • 2019/05/14 Summary of Financial Results 2019 pdf (399KB)
  • 2019/03/29 Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan pdf (194KB)
  • 2019/02/08 Corporate Governance Report pdf (496KB)
  • 2019/02/06 【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED] pdf (932KB)
  • 2019/01/30 Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase) pdf (259KB)
  • 2019/01/30 Summary of Financial Results for the third quarter 2019 pdf (488KB)
  • 2018/12/17 Notice Regarding Transfer of Mushroom Business pdf (316KB)
  • 2018/11/14 We have posted "Financial Results Presentation". pdf (684KB)
  • 2018/11/06 Consolidated Financial Statements for the Second Quarter Ended September 30, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED] pdf (728KB)
  • 2018/11/06 Summary of Financial Results for the second quarter 2019 pdf (390KB)
  • 2018/09/28 【Delayed】Notice Regarding Business Reorganization by Simplified Absorption-type Company Split pdf (241KB)
  • 2018/09/03 We have issued "Annual Report 2018". pdf (2,549KB)
  • 2018/08/22 Takara Bio entered into a licensing agreement relating to Oncolytic Virus "Canerpaturev" with Dong-A ST, South Korea pdf (195KB)
  • 2018/07/31 Consolidated Financial Statements for the First Quarter Ended June 30, 2018 FY2019(April 1, 2018-March 31, 2019)[UNAUDITED] pdf (182KB)
  • 2018/07/31 Summary of Financial Results for the first quarter 2019 pdf (109KB)
  • 2018/06/08 【Delayed】Announcement on revision of Takara Bio Medium-Term Management Plan FY2020 pdf (533KB)
  • 2018/06/08 【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2018 FY2018 (April 1, 2017 - March 31, 2018)[UNAUDITED] pdf (780KB)
  • 2018/02/13 【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2017 FY2017 (April 1, 2017 - March 31, 2018) [UNAUDITED] pdf (832KB)
  • 2018/01/30 Summary of Financial Results for the third quarter 2018 pdf (96KB)
  • 2017/11/28 Consolidated Financial Statements for the Second Quarter Ended September 30, 2017 pdf (1,571KB)
  • 2017/11/06 Revision of Consolidated Business Results Forecast for the First Half of the Fiscal Year Ending March 31, 2018 pdf (221KB)
  • 2017/08/21 Consolidated Financial Statement for the First Quarter Ended June 30, 2017 pdf (891KB)
  • 2017/07/27 Summary of Consolidated Financial Statement for the First Quarter Ended June 30, 2017 pdf (367KB)
  • 2017/05/09 Consolidated Financial Statement for the year ended March 31, 2017, released on May 9, 2017 pdf (791KB)
  • 2017/05/09 Formulation of Takara Bio Medium-Term Management Plan FY2020 pdf (243KB)

Back to List

PAGETOP
PAGETOP
  • CLOSE
  • MENU

サイト内検索

  • footer-content
  • menu
  • JA
  • EN
  • contact
  • gnavi-box